Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation

Carcinomas of unknown primary (CUPs) have poor prognosis due to the paucity of data on their clinical characteristics and laboratory features, and empirical chemotherapy still remains the critical management for this kind of disease. This study aimed to present the knowledge of treating an elderly m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Jing-hao, Wang, An-sheng, Wang, Xiao-jing, Zhang, Lu, Zhu, Yue, Ou, Yu-rong, Wang, Zi-shu, Yang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549664/
https://www.ncbi.nlm.nih.gov/pubmed/31213843
http://dx.doi.org/10.2147/OTT.S202739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549664/
https://www.ncbi.nlm.nih.gov/pubmed/31213843
http://dx.doi.org/10.2147/OTT.S202739

Ejemplares similares